Navigation Links
Children's Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)
Date:9/29/2011

hilanthropic resources to go directly to COG's worldwide team of researchers committed to turning new discoveries into better treatments.

About Apeiron (as of September 2011):

Apeiron is a privately financed biotech based in Vienna, Austria. Apeiron focuses on biological and immunological treatments against cancer and related conditions. Including the recently closed licence agreement for the phase III project Mab ch14.18/CHO (APN311), Apeiron's project portfolio consists of five projects under clinical evaluation, and four preclinical projects. Clinical projects include the immunocytokine hu14.18-IL2 (APN301) that is about to enter a phase II (for certain neuroblastoma patients) shortly and is also being clinically tested against melanoma. Also in clinical stage is a liposomal formulation of recombinant human Superoxide Dismutase (APN201) to prevent or treat skin damage due to radiation treatment in cancer. A further clinical project, recombinant human Angiotensin Converting Enzyme 2 (APN01), was licensed to GlaxoSmithKline early 2010. It is expected to commence a phase II study for the treatment of Acute Respiratory Distress Syndrome in the near future and has considerable potential in other disease areas. Apeiron is operational since 2006 and employs approx. 25 people.

About APN301:

APN301 (hu14.18-IL2) is a recombinant fusion protein that consists of the humanized 14.18 monoclonal antibody, which recognizes the GD2 disialoganglioside, strongly expressed on virtually all cases of human neuroblastoma, as well as on several other human cancer types (including melanoma, small cell lung carcinoma, osteosarcoma, and soft-tissue sarcoma), linked genetically to human recombinant interleukin-2 (IL2) lymphokine. IL2 has been tested extensively in clinical cancer trials and is approved as an immune activator with documented anti-tumor effects in certain cancers (melanoma and renal cell cancer).

In patients, hu14.18-IL2 localizes to GD2-po
'/>"/>

SOURCE APEIRON Biologics AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. XECAN and Trimble Partner to Deliver ThingMagic Powered RFID Oncology Solution
2. Champions Oncology Clarifies Misstatements in News Article
3. Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar
4. Champions Oncology Reports Full Year 2011 Financial Results
5. McKesson Specialty Care Solutions
6. US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work
7. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
8. Oncology National Commercial (ONC) Study Outlines 10 Trends Shaping the Market for Oncology Pharmaceutical and Biotech Products
9. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Beardsworth Continues to Strengthen Oncology Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... MIAMI , Aug. 26, 2015  The ... at the University of Miami Miller School of ... its clinical trial to test for the first ... was successfully completed.  This FDA approved Phase I/II ... islet transplantation and is an important first step ...
(Date:8/26/2015)... 26, 2015 Israel Proves Its Place in ... st place  Wayerz comes in 5 th ... by venture capital fund JVP, with Chinese consulting firm ... China , Israel , ... Impressive achievement for the Israeli representatives in the final round ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... havoc on bacteria as well as humans and, just like ... Professor John van der Oost, at the Society for General ... system" could be used to keep industrial microbes at peak ... Wageningen University in the Netherlands have spent the last three ...
... ... minutes post-dose using electronic patient diary data , ... PITTSBURGH, PA (Vocus) March 31, 2010 -- invivodata, ... global clinical research, today announced that its DiaryPRO® field-based ePRO solution captured ...
... system senses and tracks down infection in the body by ... cells manipulate their movement in response to external signals could ... but also how cancer cells spread through the body and ... Society for General Microbiology,s spring meeting in Edinburgh, Dr Holger ...
Cached Biology Technology:invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial 2invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial 3How immune cells 'sniff out' bacteria 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... which become accustomed to ignoring genetically engineered chemical alarms ... become easy prey for ladybugs. That,s good news for ... for Plant Research and Cornell University. ( Proceedings of ... The study, "Alarm pheromone habituation in Myzus persicae ...
... Research is continually emerging on the impacts ... ecosystems and communities. Ecological scientists will discuss widespread ... plants in the wild to the implications of ... exploring society,s reactive mode toward environmental disasters in ...
... cell division, microtubules emanating from each of the spindle ... Scientists at the European Molecular Biology Laboratory (EMBL) in ... the extent of this overlap. In a study published ... reconstruct such anti-parallel microtubule overlaps in vitro, and identify ...
Cached Biology News:Apathetic aphids with attitude become easier prey for ladybugs 2Scientists find new evidence of genetically modified plants in the wild 2Scientists find new evidence of genetically modified plants in the wild 3Scientists find new evidence of genetically modified plants in the wild 4Constant overlap 2